Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Icon Plc (ICLR)

Icon Plc (ICLR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,913,151
  • Shares Outstanding, K 80,757
  • Annual Sales, $ 8,282 M
  • Annual Income, $ 791,470 K
  • EBIT $ 1,201 M
  • EBITDA $ 1,690 M
  • 60-Month Beta 1.28
  • Price/Sales 1.09
  • Price/Cash Flow 5.33
  • Price/Book 0.92

Options Overview Details

View History
  • Implied Volatility 89.33% (-0.88%)
  • Historical Volatility 41.89%
  • IV Percentile 99%
  • IV Rank 98.46%
  • IV High 90.21% on 04/13/26
  • IV Low 33.15% on 07/25/25
  • Expected Move (DTE 3) 6.51 (5.76%)
  • Put/Call Vol Ratio 0.10
  • Today's Volume 866
  • Volume Avg (30-Day) 487
  • Put/Call OI Ratio 0.81
  • Today's Open Interest 11,375
  • Open Int (30-Day) 8,375
  • Expected Range 106.55 to 119.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $2.99
  • Number of Estimates 3
  • High Estimate $3.10
  • Low Estimate $2.82
  • Prior Year $3.07
  • Growth Rate Est. (year over year) -2.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
95.75 +18.08%
on 03/19/26
115.63 -2.22%
on 04/02/26
+14.73 (+14.98%)
since 03/13/26
3-Month
66.57 +69.84%
on 02/12/26
191.00 -40.81%
on 01/27/26
-71.71 (-38.81%)
since 01/14/26
52-Week
66.57 +69.84%
on 02/12/26
211.00 -46.42%
on 07/24/25
-33.68 (-22.95%)
since 04/14/25

Most Recent Stories

More News
ICON's April Thirtieth Verdict: Can the CRO Survive Its Own Audit?

Barchart Research What to Expect from ICLR Earnings ICLR Generated March 31, 2026 Current Price $110.66 EPS Estimate $$3.16 Consensus Rating Moderate Buy Average Move 8.86% ICON's April Thirtieth Verdict:...

ICLR : 113.06 (+2.44%)
Icon Plc Faces Earnings Test After Accounting Scandal and Analyst Downgrades

ICLR : 113.06 (+2.44%)
ICON and Advarra Introduce New ‘Research-Ready,’ Connected Site Network Model

Partnership will integrate ICON’s clinical trial technology with Advarra’s purpose-built system for research sites, embedded across a broad, deeply established global network. ...

ICLR : 113.06 (+2.44%)
ICLR ALERT: Ongoing Investigation Into ICON Public Limited Company - Contact Levi & Korsinsky

New York, New York--(Newsfile Corp. - March 16, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ICON Public Limited Company (NASDAQ: ICLR) ("ICON Public Limited...

ICLR : 113.06 (+2.44%)
Lost Money on ICON Public Limited Company (ICLR)? Possible Fraud - Contact Levi & Korsinsky Today

New York, New York--(Newsfile Corp. - March 9, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ICON Public Limited Company ("ICON Public Limited Company") (NASDAQ:...

ICLR : 113.06 (+2.44%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICON plc - ICLR

NEW YORK , March 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ICON plc ("ICON" or the "Company") (NASDAQ: ICLR). Such investors are advised to contact...

ICLR : 113.06 (+2.44%)
Lost Money on ICON Public Limited Company (ICLR)? Possible Fraud - Contact Levi & Korsinsky Today

New York, New York--(Newsfile Corp. - March 2, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ICON Public Limited Company ("ICON Public Limited Company") (NASDAQ:...

ICLR : 113.06 (+2.44%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICON plc - ICLR

NEW YORK , Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ICON plc ("ICON" or the "Company") (NASDAQ: ICLR). Such investors are advised to contact...

ICLR : 113.06 (+2.44%)
ICLR INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving ICON Public Limited Company

The law firm of Kirby McInerney LLP continues its investigation on behalf of ICON Public Limited Company (“ICON” or the “Company”) (NASDAQ:ICLR) investors concerning the Company’s...

ICLR : 113.06 (+2.44%)
Protect Your Investment: Contact Levi & Korsinsky About the ICON Public Limited Company (ICLR) Investigation

New York, New York--(Newsfile Corp. - February 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ICON Public Limited Company ("ICON Public Limited Company") (NASDAQ:...

ICLR : 113.06 (+2.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide.

See More

Key Turning Points

3rd Resistance Point 118.85
2nd Resistance Point 116.57
1st Resistance Point 114.81
Last Price 113.06
1st Support Level 110.78
2nd Support Level 108.50
3rd Support Level 106.74

See More

52-Week High 211.00
Fibonacci 61.8% 155.83
Fibonacci 50% 138.78
Fibonacci 38.2% 121.74
Last Price 113.06
52-Week Low 66.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.